Common Contracts
2 similar Sublicense Agreement contracts by Audentes Therapeutics, Inc.
COLLABORATIVE DEVELOPMENT AGREEMENT No. 013135-1MTUB-00Sublicense Agreement • January 4th, 2016 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • England and Wales
This COLLABORATIVE DEVELOPMENT AGREEMENT (the “Agreement”), effective as of January 24, 2014 (the “Effective Date”), is made by and between Audentes Therapeutics, Inc., a Delaware corporation, having a place of business at 101 Montgomery Street, Suite 2650, San Francisco, CA 94104, USA (“Audentes”) and Genethon, a French not-for-profit organization organised under the French law of July 1, 1901, having a principal place of business at 1bis rue de l’Internationale, 91002 EVRY Cedex, France (“Genethon”).
COLLABORATIVE DEVELOPMENT AGREEMENT No. 013135-1MTUB-00Sublicense Agreement • December 18th, 2015 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • England and Wales
This COLLABORATIVE DEVELOPMENT AGREEMENT (the “Agreement”), effective as of January 24, 2014 (the “Effective Date”), is made by and between Audentes Therapeutics, Inc., a Delaware corporation, having a place of business at 101 Montgomery Street, Suite 2650, San Francisco, CA 94104, USA (“Audentes”) and Genethon, a French not-for-profit organization organised under the French law of July 1, 1901, having a principal place of business at 1bis rue de l’Internationale, 91002 EVRY Cedex, France (“Genethon”).
